Illumina updates NovaSeq X series
February 2025—Illumina announced a series of updates to its NovaSeq X series, including the NovaSeq X single-flow-cell system, a software upgrade, and new kits.
Webinars and Sponsored Roundtables — Register Now
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
ARUP launches assay for influenza A (H5) virus
February 2025—ARUP Laboratories has launched an assay for the detection and subtyping of influenza A (H5) virus. The test will aid in the evaluation of people who may have been exposed to highly pathogenic avian influenza (HPAI) A virus, also known as H5N1 or bird flu.
OGT launches NGS SureSeq Myeloid MRD panel
February 2025—OGT announced the North American launch of its next-generation sequencing SureSeq Myeloid MRD panel. The ultra-sensitive panel enables the detection of 13 key measurable residual disease–associated biomarkers in acute myeloid leukemia. Ultralow variant detection, including for very large FLT3-ITDs, enables a stronger characterization of a sample’s current AML status. The company’s complimentary NGS analysis software, Interpret, is available on the cloud or as a local install and provides a powerful bioinformatic analysis pipeline.
Qiagen EZ2 Connect reaches milestone of more than 1,000 placements
February 2025—Qiagen announced it has reached a milestone of having more than 1,000 placements of the EZ2 Connect automated sample preparation instrument. Launched in 2021, the EZ2 Connect is designed to automate the entire process of nucleic acid purification, reducing hands-on time and increasing throughput while maintaining high precision and reproducibility. The company says the system is particularly beneficial for laboratories handling medium volumes of samples for use across a range of downstream molecular biology research applications, such as digital PCR and next-generation sequencing.
BioMérieux acquires immunoassay start-up SpinChip
February 2025—BioMérieux has entered into an agreement to acquire SpinChip Diagnostics (Oslo, Norway), a privately held company that has developed an immunoassay diagnostics platform that can deliver results from a whole blood sample within 10 minutes. SpinChip is initially developing lab-quality tests to address indications common in acute care settings, such as myocardial infarction, and will first focus on high-sensitive troponin I, NT-proBNP, and D-dimer.
Sysmex to distribute, service Sentinel SentiFIT in Canada
February 2025—Sysmex America has signed an agreement with Sentinel Diagnostics that grants Canadian rights to distribute and service Sentinel Diagnostics SentiFIT 270 and 800 analyzers as part of a new fecal immunochemical test.
Beckman Coulter RUO assays for neurodegenerative diseases
February 2025—Beckman Coulter Diagnostics announced the availability of research use only blood-based biomarker immunoassays intended to assess phosphorylated tau217, glial fibrillary acidic protein, neurofilament light chain, and apolipoprotein ε4 biomarkers. These neurogenerative RUO assays are available for use on the DxI 9000 immunoassay analyzer. The GFAP, NfL, and APOE ε4 assays are also available for use on the Access 2 immunoassay analyzer.
Adaptive, NeoGenomics sign multiyear collaboration
February 2025—Adaptive Biotechnologies Corp. and NeoGenomics announced a multiyear exclusive strategic commercial collaboration that aims to advance minimal residual disease monitoring options for patients with select blood cancers.
Genomadix gets Health Canada license for Cube CYP2C19 system
Februrary 2025—Genomadix announced it has received a medical device license from Health Canada permitting marketing of its Genomadix Cube CYP2C19 system, an automated sample-to-result PCR test. The test can be used to aid clinicians in determining a therapeutic strategy for drugs metabolized by the CYP450 2C19 genetic pathway. The Genomadix Cube CYP2C19 system identifies the CYP2C19 *2, *3, and *17 alleles directly from buccal swabs in about an hour.
Qiagen launches QIAcuityDx dPCR system
January 2025—Qiagen announced the launch of the QIAcuityDx digital PCR system, an IVD medical device that integrates partitioning, thermocycling, and imaging into a streamlined five-plex workflow. The nanoplate-based workflow disperses a sample into thousands of tiny partitions and then reads reactions simultaneously to quantify signals from DNA and RNA.